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Abstract
Background: To construct safer recombinant flavivirus vaccine, we exploited Japanese encephalitis virus (JEV)
replicon-based platform to generate single-round infectious particles (SRIPs) that expressed heterologous neutralizing
epitope SP70 derived from enterovirus-71 (EV71). Such pseudo-infectious virus particles, named SRIP-SP70, although are
not genuine viable viruses, closely mimic live virus infection to elicit immune responses within one round of viral
life cycle.
Results: We found that, besides gaining of full protection to thwart JEV lethal challenge, female outbred ICR mice,
when were immunized with SRIP-SP70 by prime-boost protocol, could not only induce SP70-specific and IgG2a
predominant antibodies but also provide their newborns certain degree of protection against EV71 lethal challenge.
Conclusions: Our results therefore exemplify that this vaccination strategy could indeed confer an immunized host a
dual protective immunity against subsequent lethal challenge from JEV or EV71.
Keywords: Japanese encephalitis virus (JEV), Replicons, Single-round infectious particles (SRIPs), RNA vaccine,
Enterovirus-71 (EV71), Neutralizing epitope, SP70, Dual protective immunity
Background
Using whole virus particles, conventional live-attenuated
or inactivated vaccines have succeeded effective control
of several viral infections [1]. To improve vaccine safety
and availability, nucleic acid vaccines, including DNA,
RNA and engineered viral vectors have emerged as the
next generation vaccine strategy for they can effectively
mimic vaccination with a live-attenuated virus but with-
out its potential complications [2]. As RNA viral vectors
are deliberately engineered to contain subgenomic repli-
cons lacking viral structural protein genes, single-round
infectious particles (SRIPs) can be therefore produced in
the presence of viral structural proteins that are provided
in trans by packaging cell line. Those self-replicating RNA
replicons were mostly derived from positive-sense RNA
viruses, such as Semliki Forest virus, Sindbis virus, polio-
virus, tick borne encephalitis virus (TBE), Kunjin virus,
and bovine viral diarrhea [2]. The technology of SRIP
generation facilitates a rapid and simple engineering of
recombinant antigen expression without handling infec-
tious progenies, which appears to be the essence for the
next generation vaccine development.
Japanese encephalitis virus (JEV) belongs to a family
Flaviviridae genus Flavivirus, which is an enveloped,
positive sense, single-stranded RNA virus with an 11-kb
genome that encodes three structural proteins of capsid
(C), pre-membrane (prM) and envelope (E) and seven
non-structural proteins of NS1 to NS5. Of them, prM, E
and NS1 proteins could confer the immunized mice a
protective immunity against lethal JVE challenge [3]. NS1
is not only expressed on the surface of the infected cells
but also secreted outside from infected cells [4]. Because
of its high immunogenic nature, NS1 alone is sufficient to
trigger protective immunity against subsequently lethal
JEV challenges [5].
JEV SRIPs have been shown to be protective against
homologous lethal challenges for newborns that were born
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to the immunized dams [6]. Chimeric flavivirus SRIPs of
TBE and JEV that included heterologous antigens were
previously established [7–9]. SRIP vaccines seem to be cap-
able of inducing better immune responses than their
inactive vaccine counterparts, and more importantly, SRIP
vaccines appear to be safer than live attenuated counter-
parts [6, 10]. Characteristically, JEV vaccines, both live
attenuated and inactivated forms, are highly effective and
safe among several flavivirus vaccines that currently are
routinely used by many Asian and South Asian Counties. It
is therefore tempting to develop dual/multiple protective
vaccines using JEV genome as a backbone for insertion and
expression of heterologous epitopes of interest.
Enterovirus 71 (EV71) together with JEV are the major
viral pathogens that attack the central nervous system
(CNS) and may cause severe encephalitis in children and
young adults in many Asian Countries [11, 12]. Neutraliz-
ing epitopes, SP55 (amino acids 163–177) and SP70 (amino
acids 208–222) derived from structural protein VP1, have
been identified to elicit protective immunity against lethal
EV71 challenge in neonatal mice from their immunized
mothers [13]. SP70 appears to be especially conserved
among various sub-genomic groups of different EV71
strains [13, 14]. We in this study exploited JEV replicon-
based platform to generate SRIPs, which were designed to
express NS1-fusion proteins containing heterologous neu-
tralizing epitope SP70 from EV71. Such pseudo-type virus
particles even though are not genuine viable viruses, can
imitate a live virus infection to elicit immune responses
from the given hosts within one round of viral life cycle.
The vaccine strategy of this kind hence provides a dual




JEV was recovered from BHK-21 cells transfected with
RP-9 infectious cDNA clone (rRP-9) [15] and then was
propagated in mosquito C6/36 cells cultured by RPMI 1640
medium containing 5 % fetal bovine serum (FBS, GIBCO).
MP4 was a mouse-adapted EV71 strain and grown in
Rhabdomyosarcoma (RD) cells in complete Dulbecco’s
modified Eagle’s medium/high glucose (DMEM/HG,
GIBCO) containing 10 % FBS and 2 mM L-glutamine
(GIBCO) [16], which was a kind gift from Dr. Shin-Ru Shih
at Chang Gung University, Taiwan. African green monkey
kidney (Vero) cells (a kind gift from ADIMMUNE Cor.,
Taiwan) were grown in MEM with Earle’s Balanced Salt
Solution (MEM/EBSS, GIBCO) supplemented with 10 %
FBS and 2 mM L-glutamine.
Construction of JEV DNA-based replicons
To generate JRP and JRPSP70, the genes of Renilla lucifer-
ase (RLuc) and 2A-protease were deleted from previously
reported replicons of J-R2A [17]. SP70 epitope was fused
with NS1 at its C-terminus using Age1 and Kpn1 and
R2ASP70 resulted. Nucleotides from 198–2387 corre-
sponding to most of the structural proteins CprME were
deleted from all JEV replicons used in this study, which
also retained capsid-coding sequences from nucleotides
1–197 for genomic RNA cyclization during replication
and E-coding sequences from nucleotides 2388–2477 to
be a signal sequence for NS1.
Packaging cells for SRIPs
The PCR fragment of JEV CprME genes amplified from
rRP-9 infectious clone was cloned into a lentivirus-ex-
pression-vector, pLKO_AS3w-puro (RNAi Consortium,
Academia Sinica, Taipei, Taiwan) at restriction sites of
AscI and PstI to construct a plasmid named JCprME-
pLKO_AS3w-puro. HEK293NT cells were then co-
transfected with packaging pCMVΔR8.91, envelope
VSV-G pMD.G, and JCprME-pLKO_AS3w-puro to pro-
duce lenti-pseudoviral particles. Vero cells were trans-
duced by these pseudoviral particles to integrate CprME
gene into the genome and then were selected by 10 μg/ml
puromycin (Sigma-Aldrich) in MEM supplemented with
10 % FBS and 2 mM L-glutamine with replacement of the
medium everyday. Cells were cultured for 2 to 4 weeks
and puromycin-resistant colonies were obtained.
Preparation of JEV SRIPs and titration
To generate SRIPs, JCprME cells were transfected with
400-ng JRP or JRPSP70 using the Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s
instructions. At day six, the cultured supernatants de-
note as passage 0 (P0) were harvested and centrifuged to
remove cell debris at 1200 rpm for five minutes. SRIPs
from P0 were amplified by consecutive passages in
JCprME cells at MOI 0.1 in 1X MEM plus 2 % FBS, and
SRIPs in the supernatants were often harvested at days
seven post-infection and then were further concentrated
by hollow fiber tangential flow filtration (100 kDa
MACO, 115 cm2, modified Polyethersulfone, Spectrum
laboratories, Rancho Dominguez, CA).
SRIP or SRIP-SP70 titers were determined by immu-
noplaque assay. Briefly, CprME cells grown in 6-well
plates were infected by the indicated SRIP in a 10-fold
serial diluted manner. After 1 h at 37 °C, the infected
cells were washed twice with 1X PBS and then overlaid
with 1 % agarose (SeaPlaque®, Agarose, Lonza) contain-
ing MEM with 2 % FBS. After 4 days incubation, the
cells in 6-well plates were fixed by 10 % formaldehyde
for 1 h, washed three times with 1X PBS contain 0.1 %
tween 20, and permeabilized with 1 % Triton X-100 for
10 min. To view plaques, these cells were stained with
anti-JEV NS1 plus alkaline phosphatase-conjugated sec-
ondary antibody (Sigma-Aldrich) by adding NBT/BCIP
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substrate (Promega) to develop the color. SRIPs were ti-
trated manually as plaque forming units per ml (PFU/ml).
Western blot analysis
Protein samples from infected cells or supernatants were
mixed with 1X lysis buffer (proJET® Mammalian Cell lysis
reagent, Fermentas) containing 1X protease inhibitor
(cOmplete™, Roche). The samples were treated without or
with boiling, separated by 10 % SDS-polyacrylamide gel
electrophoresis, and transferred to a PVDF membrane
(Immobilon®-P, Millipore). The membranes were blocked
with 5 % non-fat skim milk in PBST and then reacted with
the primary antibodies of JEV specific NS1 (1:1000; J2-54),
E (1:1000; J1-85) monoclonal antibodies (MAb), or EV71-
VP1 polyclonal antibody (PAb) (1:500; PAB7630-B01P,
Abnova). The resulting blots were treated with a horserad-
ish peroxidase-conjugated secondary antibody (1:5000;
Jackson ImmunoResearch Laboratories, Inc), and visible
signals were developed by enhanced chemiluminescence
(ECL, immobilon® Western, Mllipore).
Indirect immunofluorescence assay (IFA)
To see spreading capability of SRIP, JCprME cells in
6-well plates were infected by 25-PFU of the given SRIPs,
and after incubation for the indicated time points, the
infected cells were fixed with menthol and acetone (1:1)
solution for five minutes at room temperature and then
washed twice with PBS plus 5 % skim milk. The primary
JEV-specific NS1-MAb, J2-54 (1:1000), in 5 % skim milk/
PBS was added for 2 h at room temperature, washed with
PBS, and then incubated with FITC-conjugated secondary
goat anti-mouse antibodies (1:1000; Jackson Immuno
Research Laboratories, Inc) for 1 h at room temperature.
Finally, the cells were stained with DAPI (1:1000; Sigma-
Aldrich) and imaged by a fluorescence microscope (Nikon
Eclipse TE2000- U, Tokyo, Japan).
Mouse immunization and serum sample collection
Group of 5-week-old ICR female mice (BioLASCO
Experimental Animal Center, Taipei, Taiwan) were
intra-peritoneally (i.p.) immunized with the negative
control PBS, SRIP or SRIP-SP70. For prime-boost
immunization protocol, the second dose of the same
antigen was given at 2 weeks afterward. Serum samples
were collected from facial vein at weeks 2, 4, 6, and 8. The
sera were heated at 56 °C for 30 min to inactivate comple-
ments and then stored at −80 °C until use. All
experiments were performed in the AAALAC-accredited
Center of Laboratory Animals at the National Defense
Medical Center, Taipei, Taiwan. All animal experiments
were carried out according to the guidelines outlined by
Council of Agriculture, Executive Yuan, Republic of
China. The animal protocol was approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
National Defense Medical Center with permit numbers
IACUC-14-118 and IACUC-14-254.
Serum specific anti-SP70 IgG
The total anti-SP70 IgG and their subtypes were
examined by an enzyme-linked immunosorbent assay
(ELISA). Briefly, 96-well ELISA plates (Costar) were
coated with 10 μg/ml of synthetic SP70 peptide (purchased
from NIIDV peptide synthesis core facility in Taiwan) as
antigen for overnight at 4 °C. Plates were washed once with
PBST (0.05 % Tween 20 in PBS) and then blocked with 5 %
non-fat skim milk/PBS for 2 h. After incubation, plates
were washed twice with PBST. The two-fold serially diluted
sera (27 to 215) in 1 % BSA/PBS were added, and after
incubation for 2 h and six times of washes, the secondary
antibody was added, in which horseradish-peroxidase
(HRP)-conjugated goat anti-mouse IgG (1:5000 dilution,
Cappel Laboratories, Malvern, PA) was for total IgG
titration and affinity purified HRP-conjugated rabbit anti-
mouse was for IgG1, IgG2a, or IgG2b (1:2000 dilution,
ZYMED® Laboratories, South San Francisco, CA). Plates
were washed eight times with PBST and color was devel-
oped by adding 3,3′, 5,5′- tetramethylbenzidine (TMB)
substrate (KPL) for 20 min, stopped with 1 N H2SO4, and
detected at an optical density (OD) of 450 nm by ELISA
plate reader. For the total anti-SP70 IgG and subtypes IgG
titration, the positive OD value was obtained by cutting
off 1.5 times of OD values from group of PBS-immunized
serum.
Lethal challenge
Because EV71 infection caused no apparent clinical
symptoms in adult ICR mice, one-day-old ICR mice
were used for lethal challenge using EV71 MP4. Groups
of 5-week-old female ICR mice were immunized with
PBS, SRIP or SRIP-SP70 and for prime-boost protocol
the mice were received the second immunization of the
same antigens 2 weeks afterward. Mice were allowed to
mate at the day when the final immunization was com-
pleted. Within 24 h, the one-day-old neonatal mice were
challenged i.p. with EV71/MP4 (4 LD50) or JEV rRP-9
(1 × 103 PFU) virus in 50 μl/mouse. The survival rates
were monitored daily for 14 days.
Statistical analysis
The data were presented as the mean ± the standard error.
Statistical significance was determined using GraphPad
Prism 6.0 software (GraphPad Software, San Diego, CA)
for data analysis. In vitro data from cell-based experiments
were analyzed by unpaired t test. p < 0.05 was considered
significant.
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Results
Construction of JEV-based replicon expressing EV71
neutralizing epitope SP70 and establishment of replicon
packaging cells JEV-CprME
Starting from our previous replicons J-R2A [17] and
J-R2ASP70, from which the genes of Renilla luciferase
(RLuc) and 2A-protease were deleted and the new repli-
cons of JRP and JRPSP70, respectively, resulted (Fig. 1a).
To package replicon RNA genomes into SRIPs, we engi-
neered Vero cells to stably express JEV CprME proteins
by lentovirual system, and after puromycin selection for
a proper time period, the stable cells, named JCprME,
were constructed, which could accurately express JEV-E
proteins as evidenced by Western blotting and immuno-
fluorescent assay (Fig. 1b).
Generation of SRIPs from JEV-based replicons could replicate
and spread within packaging cells JCprME
To generate pseudo-type virus particles, we transfected
JCprME cells with plasmid containing JRP or JRPSP70
replicon, and supernatants from the transfected cells were
harvested on days 6 post-transfection for collection of SRIP
and SRIP-SP70. We next infected Vero or JCprME cells
with SRIP or SRIP-SP70 to see how these pseudo-type virus
particles replicated and dispersed in cultured cells. Based
on immunofluorescence analysis using anti-JEV NS1 MAb,
we found that SRIP or SRIP-SP70 could only replicate once
but without scattering around in Vero cells with time
(Fig. 2a, upper panel). In contrast, both SRIP and SRIP-
SP70 could replicate and disperse in JCprME cells as time
went by (Fig. 2a, lower panel). Similar plaque morphology
of SRIP and SRIP-SP70 could be seen when grown on
JCprME cells by immunoplaque assay (Fig. 2b). These
results clearly demonstrate that the pseudo-type SRIP and
SRIP-SP70 can indeed only replicate once in normal cells.
Normal multimeric NS1-fusion proteins could be produced
from SRIP-SP70 infected JCprME cells
Since flavivirus NS1 is highly immunogenic to the host
due to its multimeric formation [5], we examined the
Fig. 1 JEV-based replicons and JEV-CprME packaging cells. a Schematic diagrams of JEV-based replicons. JEV infectious cDNA driven by CMV promoter
encodes three structural (gray box) and seven nonstructural (open boxes) proteins. JRP was derived from JEV infectious cDNA by deletion of nucleotides
from 198–2387, where most of structural proteins were deleted. JRPSP70 included a SP70 epitope (red box) that was fused at C-terminal of NS1. b The
packaging cells, named JCprME, were created by using pseudo-lentiviral particles containing structural genes CprME to infect Vero cells
and were selected by puromycin. The E-expression of JCprMC cells was determined by Western blot (left panel) and IFA (right panel)
using MAb against JEV E protein, and Vero cells served as a negative control. Samples from rRP-9-infected lysates serve as a positive
control for protein position of E. The arrow denotes the position of E proteins. Scale bar is 50 μm in length
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effects of EV71 epitope insertion on dimerization and
secretion of NS1-SP70 fusion proteins during infection.
We first infected JCprME cells with SRIP-SP70 in
multiple-passage manner, and the viral antigens in cell
lysates or culture medium were collected for western
blotting using antibodies specifically recognizing JEV-
NS1 or EV71-VP1. These protein samples were prepared
through either being boiled to detect monomeric or
leaving unboiled to detect dimeric NS1-EV71-epitope fu-
sion proteins. NS1’, a longer version of NS1 was the re-
sult from a ribosomal frame-shifting mechanism, is only
expressed by JE serocomplex flaviviruses including JEV
[18]. As compared with the parental virus rRP-9 shown
in Fig. 3, all NS1-SP70 fusion proteins from the indi-
cated SRIP-SP70 also had a longer NS1’ version, could
properly dimerize in both intracellular and extracellular
unheated samples (Fig. 3, the left parts of panels a and
b), and were readily secreted from infected cells (panel
B). Importantly, we found that all SRIPs could secrete
soluble NS1 and NS1’ in their correct multimeric forms
as their parental rRP-9, from infected cells (Fig. 3). To-
gether, these results clearly illustrate that fusion of heter-
ologous epitopes with JEV-NS1 does not impair the
abilities of SRIP-SP70 in terms of NS1’ processing, NS1
dimerization and secretion.
SRIP-SP70 could confer a dual immunity against JEV or
EV71 lethal challenges
To examine whether immunization of SRIP or SRIP-
SP70 could protect mice from homologous JEV lethal
challenge, we inoculated 1 × 103 PFU of JEV rRP-9 to
groups of one-day-old newborn mice borne to their
immunized mothers. We found that all the newborns
from dams that were immunized with 5 × 107 PFU of
SRIP or SRIP-SP70 could survive, whereas all the new-
borns from PBS-immunized dams were killed within
6 days after the lethal challenge of JEV rRP-9 (Fig. 4, the
left part of panels a and b). It remained 100 % protective
when the immunized dose was reduced to 1 × 105 PFU
of SRIP or SRIP-SP70 (data not shown).
As EV71 infection caused no apparent clinical symp-
toms in adult ICR mice [19], we opted to intra-peritoneally
challenge one-day-old ICR mice by a mouse-brain adapted
strain EV71/MP4, whose 50 % lethal dose (LD50) was
approximately 32 PFU and the minimum lethal dose to kill
all infected newborns was 4 LD50. To investigate whether
SRIP-SP70 could also protect the immunized mice from
heterologous EV71 lethal challenge, again, we intra-
peritoneally injected a lethal dose of EV71/MP4 to groups
of one-day-old ICR newborns from their mothers immu-
nized with PBS alone, or 5 × 107 PFU of either SRIP-SP70
or SRIP as a control. We found that, compared with con-
trols of PBS or SRIP immunization, when we used the SRIP
immunization protocol (Fig. 4a), only 8 % (4/46) of the
challenged newborns survived; in contrast, when using the
prime-boost SRIP immunization protocol (Fig. 4b), we
observed that 32 % (16/49) of the challenged newborns
survived.
To understand the specific anti-SP70 antibody responses,
we examined each immunized serum collected at different
time points by ELISA from dams using prime-boost SRIP
immunization protocol. As the results shown in Fig. 4c, the
specific serum titers from most of the pregnant mice tested
could reach the plateau 4 weeks after immunization proto-
col completed, at the period roughly one week before giving
birth. Since the serum levels of IgG2a and IgG1 are often
Fig. 2 Packaging, spreading and plaque morphology of SRIP. a Spreading of SRIPs in JCprME cells. The Vero cells (upper panel) or JCprME cells
(lower panel) were seeded in 6-well plates to reach a confluent monolayer, which were inoculated with SRIP or SRIP-SP70 for the indicated time
periods. The resulting cells were fixed for IFA using MAb specific for JEV NS1. b Plaque morphology of SRIP and SRIP-SP70 were examined at day
4 post-infection by immunoplaque assay using MAb specific for JEV NS1. Scale bar is 50 μm in length
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used to define how immunity undergoes the Th1- or Th2-
predonminant responses when the hosts are under infec-
tions, and the IgG2a/IgG1 ratios are used to predict which
T-cell phenotype can be induced by a given vaccination
[20–22]. We therefore in Fig. 4d examined levels of the
indicated subserotypes of serum specific derived from mice
at week 4 in Fig. 4c. We found that IgG2a levels from im-
munized dams were significant higher than those of IgG1
or IgG2b, and almost all IgG2a/IgG1 ratios were >1, indi-
cating a Th1-biased immune response (Fig. 4d). Interest-
ingly, we identified a non-responder, named SRIP-SP70-3,
in Fig. 4c and d, whose serum specific IgG levels were as
low as the background. Pregnant SRIP-SP70-3 subse-
quently had given birth to 13 newborns that were
included in the challenge experiment shown in Fig. 4b.
Discussion
We in this study used JEV replicon-based platform to
generate SRIPs as a vaccine, which contains JEV
subgenomic RNA wrapped by virus structural proteins
derived in trans from stable packaging JCprME cells to
form a typical pseudo virus particles. However, replicon-
based SRIP and SRIP-SP70 cannot be packaged and
spread out in Vero cells because these cells did not ex-
press CprME structure proteins that are required for
forming infectious particles. SRIPs can only replicate
within their first infected cells but not in the surround-
ing cells due to lack of CpME proteins provided in trans
by Vero cells. Starting from using replicon-containing
plasmid DNA, we first obtained small amounts of SRIPs
from the transfected JCprME cells and subsequently
could attain sufficient amounts of SRIPs through repeat
infections in JCprME cells. With a proper optimization,
this process appears to be the reliable and streamline
protocol for flaviviral RNA vaccine production.
Using the prime-boost SRIP immunization protocol
(Fig. 4b) but not the SRIP immunization (once) protocol
(Fig. 4a), we found that 32 % (16/49) of the newborns
Fig. 3 Multimeric NS1 fusion proteins derived from SRIP-SP70 infection. JCprME cells were repeatedly infected by SRIP-SP70 as indicated, and cell
lysates were prepared for detection of the intracellular NS fusion proteins (a) and supernatants were collected for detection of the extracellular NS fusion
proteins (b). Analyzed by Western blotting using NS1-specific or SP70-specific antibodies, the protein samples from cell lyastes or supernatants were left
unboiled to detect multimeric NS1 fusion proteins (the left parts of panels a and b), or being boiled to examine monomers of NS1 proteins (the right parts
of panels a and b). Samples from virus infection by rRP-9 or rRP9-SP70 serve as a positive control. Samples from JCprME were mock-infected controls. The
arrow denotes the dimer or monomer position of NS1 or NS1-SP70
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from their mothers immunized with SRIP-SP70 could
survive from the subsequent lethal EV71 challenge.
Since the control groups of PBS or SRIP immunization
in the above experiment (Fig. 4b) showed no protective
capability, we therefore conclude that the backbone of
JEV replicon plays no role in the protection against EV71
resulting from SRIP-SP70 immunization. As a result, it is
the neutralizing epitope SP70 fused with NS1 protein that
plays a critical role in providing such a protective immun-
ity from SRIP-SP70 against heterologous EV71 lethal chal-
lenge. On the other hand, we clearly illustrated that the
backbone of JEV replicons used in this study could readily
confer a complete protection from homologous JEV lethal
challenge (Fig. 4a and b). Our findings thus provide a
proof of concept about that SRIP-SP70, produced by JEV
replicon-based platform established from this study,
confers a dual protective immunity against subsequent le-
thal challenges from JEV as well as EV71 infections.
Interestingly, we later discovered that one of the
SRIP-SP70-3-immunized dams in fact appeared to be a
non-responder in terms of its extremely low serum specific
IgG responses (Fig. 4c and d), and this mouse gave birth to
13 newborns that had already been included in the above-
mentioned lethally EV71-challenged experiment (Fig. 4b).
These newborns were all killed by subsequent EV71 lethal
challenge. Since ICR mice are genetically outbred, we there-
fore consider that there should be 44 % (16/36) of the chal-
lenged newborns survived among the responders when
using prime-boost SRIP-SP70 immunization protocol.
These observations seem to suggest a positive correlation
between the titers of serum specific IgG in SRIP-SP70-
immnunized mother dams and the survival rates of their
Fig. 4 SRIP-SP70 confers dual protective immunity against JEV or EV71 challenge via Th1-predominant immune response. Survival rates were evaluated
for groups of one-day-old ICR newborns from their mothers that had been immunized with PBS alone, SRIP or SRIP-SP70 using SRIP immunization
protocol (a) or by prime-boost SRIP immunization protocol (b). These newborns were lethally challenged by either 1 × 103 PFU of JEV rRP-9 (the left
part of panels a and b) or 4 LD50 of EV71/MP4 (the right part of panels a and b). c Serum specific IgG from immunized dams. To
measure serum specific anti-SP70 IgG titers by ELISA, the SRIP-SP70-immunized sera were collected from groups of female ICR mice at
the indicated times after prime-boost SRIP immunization protocol. d Serum IgG subtyping from each pregnant mouse. The specific anti-SP70 IgG in serum
was subtyped by ELISA isotype binding assays, and each individual serum was collected and analyzed 4 week after immunization protocol completed in
(c). Data are shown as mean for group mice (n= 5). The symbols represent immunized ICR mice and parentheses indicate survival rate of newborns after
challenges. The serum titer that was less than 27 dilutions will be marked as 0. ELISA plates were coated with 10 μg/ml of synthetic SP70 peptide as
antigen. Star * indicates p value < 0.05. ND means no difference
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newborns to face EV71 challenge. An insufficient EV71-
specific Th1 response has been implied to be associated
with immunopathogenesis of EV71-related pulmonary
edema [23]. A strong cellular immunity especially biased
toward Th1 response through vaccination is thought to be
an important strategy for defeating EV71 infections. We in
this study showed SRIP-SP70 could trigger Th1-biased im-
mune response (Fig. 4d), which may thus play a protective
role in newborn mice when they were lethally challenged
by EV71. Although SP70 peptide is highly conserved
amongst many EV71 strains and the antisera raised against
SP70 were able to neutralize many different EV71 strains
[13], other neutralizing epitopes identified, such as VP2-28
[22], should be included in our platform to improve its
EV71 protection capability. However, in addition to MP4,
different EV71 strains are needed to be further tested for
the protective efficacy of SRIP-SP70 immunization in the
future.
Conclusions
Here we established JEV replicon-based platform to gen-
erate SRIP vaccine that expressed heterologous EV71
neutralizing epitope. Such pseudo-infectious virus parti-
cles, although are not genuine viruses, can closely mimic
live virus infection to elicit immune responses within
one round of viral life cycle. We found that, in addition
to thwart JEV lethal challenge, the female outbred ICR
mice immunized with JRPSP70 SRIPs by prime-boost
protocol could also provide their newborns certain degree
of protection against subsequent EV71 lethal challenge.
These results therefore clearly demonstrate that this vac-
cination strategy indeed can confer immunized hosts a
dual protective immunity against subsequent lethal chal-
lenge from JEV or EV71.
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